A citation-based method for searching scientific literature


List of co-cited articles
2 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.
Yelena Y Janjigian, Akihito Kawazoe, Patricio Yañez, Ning Li, Sara Lonardi, Oleksii Kolesnik, Olga Barajas, Yuxian Bai, Lin Shen, Yong Tang,[...]. Nature 2021
54
100

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Yelena Y Janjigian, Kohei Shitara, Markus Moehler, Marcelo Garrido, Pamela Salman, Lin Shen, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda Campos Bragagnoli,[...]. Lancet 2021
307
100

CD47: the next checkpoint target for cancer immunotherapy.
Ridong Feng, Hai Zhao, Jianguo Xu, Chongyang Shen. Crit Rev Oncol Hematol 2020
23
50

Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1).
Sook Ryun Park, Young Soo Park, Min-Hee Ryu, Baek-Yeol Ryoo, Chang Gok Woo, Hwoon-Yong Jung, Jeong Hoon Lee, Gin Hyug Lee, Yoon-Koo Kang. Eur J Cancer 2016
53
50

Monitoring circulating tumor DNA by analyzing personalized cancer-specific rearrangements to detect recurrence in gastric cancer.
Young-Woo Kim, Young-Ho Kim, Yura Song, Han-Seong Kim, Hye Won Sim, Shiv Poojan, Bang Wool Eom, Myeong-Cherl Kook, Jungnam Joo, Kyeong-Man Hong. Exp Mol Med 2019
23
50

Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial.
Alexander Stein, Lisa Paschold, Joseph Tintelnot, Eray Goekkurt, Svenja-Sibylla Henkes, Donjete Simnica, Christoph Schultheiss, Edith Willscher, Marcus Bauer, Claudia Wickenhauser,[...]. JAMA Oncol 2022
3
50

A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
Xuejing Yao, Jing Jiang, Xin Wang, Changjiang Huang, Dong Li, Kuan Xie, Qiaoyu Xu, Hongwen Li, Zhuanglin Li, Liguang Lou,[...]. Breast Cancer Res Treat 2015
50
50

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.
Josep Tabernero, Paulo M Hoff, Lin Shen, Atsushi Ohtsu, Manish A Shah, Karen Cheng, Chunyan Song, Haiyan Wu, Jennifer Eng-Wong, Katherine Kim,[...]. Lancet Oncol 2018
204
50

Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors.
Yingying Xu, Yakun Wang, Jifang Gong, Xiaotian Zhang, Zhi Peng, Xinan Sheng, Chenyu Mao, Qingxia Fan, Yuxian Bai, Yi Ba,[...]. Gastric Cancer 2021
15
50

Involvement of microRNAs in HER2 signaling and trastuzumab treatment.
Ling Mao, Ai-Jun Sun, Jian-Zhong Wu, Jin-Hai Tang. Tumour Biol 2016
13
50

CD47-signal regulatory protein α signaling system and its application to cancer immunotherapy.
Yoji Murata, Yasuyuki Saito, Takenori Kotani, Takashi Matozaki. Cancer Sci 2018
48
50


The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity.
T Akiyama, C Sudo, H Ogawara, K Toyoshima, T Yamamoto. Science 1986
738
50

Receptor protein-tyrosine kinases and their signal transduction pathways.
P van der Geer, T Hunter, R A Lindberg. Annu Rev Cell Biol 1994
50

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
Peter C Thuss-Patience, Manish A Shah, Atsushi Ohtsu, Eric Van Cutsem, Jaffer A Ajani, Hugo Castro, Wasat Mansoor, Hyun Cheol Chung, Gyorgy Bodoky, Kohei Shitara,[...]. Lancet Oncol 2017
242
50

Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
Daniel V T Catenacci, Yoon-Koo Kang, Haeseong Park, Hope E Uronis, Keun-Wook Lee, Matthew C H Ng, Peter C Enzinger, Se Hoon Park, Philip J Gold, Jill Lacy,[...]. Lancet Oncol 2020
68
50

A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model.
Tomomi Nakayama Iwata, Chiaki Ishii, Saori Ishida, Yusuke Ogitani, Teiji Wada, Toshinori Agatsuma. Mol Cancer Ther 2018
81
50

White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer.
Alessandro Leal, Nicole C T van Grieken, Doreen N Palsgrove, Jillian Phallen, Jamie E Medina, Carolyn Hruban, Mark A M Broeckaert, Valsamo Anagnostou, Vilmos Adleff, Daniel C Bruhm,[...]. Nat Commun 2020
80
50

Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion.
Bharat K R Chaganty, Songbo Qiu, Anneliese Gest, Yang Lu, Cristina Ivan, George A Calin, Louis M Weiner, Zhen Fan. Cancer Lett 2018
65
50

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Rashmi K Murthy, Sherene Loi, Alicia Okines, Elisavet Paplomata, Erika Hamilton, Sara A Hurvitz, Nancy U Lin, Virginia Borges, Vandana Abramson, Carey Anders,[...]. N Engl J Med 2020
443
50

Clinical significance of intratumoral HER2 heterogeneity in gastric cancer.
Hee Eun Lee, Kyoung Un Park, Seol Bong Yoo, Soo Kyung Nam, Do Joong Park, Hyung-Ho Kim, Hye Seung Lee. Eur J Cancer 2013
111
50


MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab.
Naohiro Nishida, Koshi Mimori, Muller Fabbri, Takehiko Yokobori, Tomoya Sudo, Fumiaki Tanaka, Kohei Shibata, Hideshi Ishii, Yuichiro Doki, Masaki Mori. Clin Cancer Res 2011
202
50

Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study.
Zhi Peng, Tianshu Liu, Jia Wei, Airong Wang, Yifu He, Liuzhong Yang, Xizhi Zhang, Nanfeng Fan, Suxia Luo, Zhen Li,[...]. Cancer Commun (Lond) 2021
14
50

AGAPP: efficacy of first-line cisplatin, 5-fluorouracil with afatinib in inoperable gastric and gastroesophageal junction carcinomas. A Hellenic Cooperative Oncology Group study.
George Zarkavelis, Epaminontas Samantas, Georgia-Angeliki Koliou, Kyriaki Papadopoulou, Davide Mauri, Gerasimos Aravantinos, Anna Batistatou, Elissavet Pazarli, Dimitrios Tryfonopoulos, Anna Tsipoura,[...]. Acta Oncol 2021
2
50

Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer.
Shusuke Yagi, Takeru Wakatsuki, Noriko Yamamoto, Keisho Chin, Daisuke Takahari, Mariko Ogura, Takashi Ichimura, Izuma Nakayama, Hiroki Osumi, Eiji Shinozaki,[...]. Gastric Cancer 2019
23
50


Assessment of a HER2 scoring system for gastric cancer: results from a validation study.
M Hofmann, O Stoss, D Shi, R Büttner, M van de Vijver, W Kim, A Ochiai, J Rüschoff, T Henkel. Histopathology 2008
823
50

FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group.
Ralf-Dieter Hofheinz, Kirsten Merx, Georg M Haag, Christoph Springfeld, Thomas Ettrich, Kersten Borchert, Albrecht Kretzschmar, Christian Teschendorf, Gabriele Siegler, Matthias P Ebert,[...]. J Clin Oncol 2022
1
100


Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.
Fernando Rivera, Marta Izquierdo-Manuel, Pilar García-Alfonso, Eva Martínez de Castro, Javier Gallego, María Luisa Limón, María Alsina, Luis López, Maica Galán, Esther Falcó,[...]. Eur J Cancer 2021
12
50

HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer.
Akio Kaito, Takeshi Kuwata, Masanori Tokunaga, Kohei Shitara, Reo Sato, Tetsuo Akimoto, Takahiro Kinoshita. World J Clin Cases 2019
22
50

An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.
Geny Piro, Carmine Carbone, Ivana Cataldo, Federica Di Nicolantonio, Simone Giacopuzzi, Giuseppe Aprile, Francesca Simionato, Federico Boschi, Marco Zanotto, Maria Mihaela Mina,[...]. Clin Cancer Res 2016
49
50

Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer.
Jian Yang, Yuhua Gong, Vincent K Lam, Yan Shi, Yanfang Guan, Yanyan Zhang, Liyan Ji, Yongsheng Chen, Yongliang Zhao, Feng Qian,[...]. Cell Death Dis 2020
34
50

First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.
Y J Bang, G Giaccone, S A Im, D Y Oh, T M Bauer, J L Nordstrom, H Li, G R Chichili, P A Moore, S Hong,[...]. Ann Oncol 2017
120
50

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.
Gulden Menderes, Elena Bonazzoli, Stefania Bellone, Jonathan Black, Federica Predolini, Francesca Pettinella, Alice Masserdotti, Luca Zammataro, Gary Altwerger, Natalia Buza,[...]. Clin Cancer Res 2017
35
50

The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor.
A L Schechter, M C Hung, L Vaidyanathan, R A Weinberg, T L Yang-Feng, U Francke, A Ullrich, L Coussens. Science 1985
486
50

HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy.
Tiziana Triulzi, Luca Forte, Viola Regondi, Martina Di Modica, Cristina Ghirelli, Maria Luisa Carcangiu, Lucia Sfondrini, Andrea Balsari, Elda Tagliabue. Oncoimmunology 2018
31
50

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.
Kohei Shitara, Jaffer A Ajani, Markus Moehler, Marcelo Garrido, Carlos Gallardo, Lin Shen, Kensei Yamaguchi, Lucjan Wyrwicz, Tomasz Skoczylas, Arinilda Campos Bragagnoli,[...]. Nature 2022
11
50

Antibody-drug conjugates to treat gastric cancer.
Shigehiro Koganemaru, Kohei Shitara. Expert Opin Biol Ther 2021
5
50

HER2-targeted therapies - a role beyond breast cancer.
Do-Youn Oh, Yung-Jue Bang. Nat Rev Clin Oncol 2020
257
50

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
Yelena Y Janjigian, Steven B Maron, Walid K Chatila, Brittanie Millang, Shweta S Chavan, Carly Alterman, Joanne F Chou, Michal F Segal, Marc Z Simmons, Parisa Momtaz,[...]. Lancet Oncol 2020
129
50

A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Huiping Li, Jiang Liu, Jianing Chen, Huiyun Wang, Linbin Yang, Fei Chen, Siting Fan, Jing Wang, Bin Shao, Dong Yin,[...]. Nat Commun 2018
60
50

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
Eric Van Cutsem, Yung-Jue Bang, Feng Feng-Yi, Jian M Xu, Keun-Wook Lee, Shun-Chang Jiao, Jorge León Chong, Roberto I López-Sanchez, Timothy Price, Oleg Gladkov,[...]. Gastric Cancer 2015
264
50

Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study).
Akitaka Makiyama, Yasutaka Sukawa, Tomomi Kashiwada, Junji Kawada, Ayumu Hosokawa, Yoshiki Horie, Akihito Tsuji, Toshikazu Moriwaki, Hiroaki Tanioka, Katsunori Shinozaki,[...]. J Clin Oncol 2020
57
50

Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.
Aman P Singh, Sharad Sharma, Dhaval K Shah. J Pharmacokinet Pharmacodyn 2016
46
50

Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer.
Nicolas Martin, Nicolas Isambert, Carlos Gomez-Roca, Rainer-Georg Goeldner, Sylvie Zanetta, Behbood Sadrolhefazi, Hélène de Mont-Serrat, Mario Campone, Jean-Pierre Delord. Cancer Chemother Pharmacol 2018
7
50

Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo.
Yanjing Song, Chuan Tong, Yao Wang, Yunhe Gao, Hanren Dai, Yelei Guo, Xudong Zhao, Yi Wang, Zizheng Wang, Weidong Han,[...]. Protein Cell 2018
40
50

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.
John Stagg, Sherene Loi, Upulie Divisekera, Shin Foong Ngiow, Helene Duret, Hideo Yagita, Michele W Teng, Mark J Smyth. Proc Natl Acad Sci U S A 2011
324
50

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Toshihiko Doi, Kohei Shitara, Yoichi Naito, Akihiko Shimomura, Yasuhiro Fujiwara, Kan Yonemori, Chikako Shimizu, Tatsunori Shimoi, Yasutoshi Kuboki, Nobuaki Matsubara,[...]. Lancet Oncol 2017
190
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.